scholarly journals Living donor liver transplantation for a patient with a history of total gastrectomy

2019 ◽  
Vol 13 (2) ◽  
pp. 212-215
Author(s):  
Keita Shimata ◽  
Tomoaki Irie ◽  
Masashi Kadohisa ◽  
Seiichi Kawabata ◽  
Sho Ibuki ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Total Gastrectomy ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
History Of

Living donor liver transplantation using a left hepatic graft from a donor with a history of gastric cancer operation

2010 ◽  
Vol 23 (2) ◽  
pp. 234-235 ◽  
Author(s):  
Hideaki Uchiyama ◽  
Mitsuo Shimada ◽  
Satoru Imura ◽  
Yuji Morine ◽  
Hirofumi Kanemura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
History Of

scholarly journals Predictive Role of the D-Dimer Level in Acute Kidney Injury in Living Donor Liver Transplantation: A Retrospective Observational Cohort Study

2022 ◽  
Vol 11 (2) ◽  
pp. 450
Author(s):  
Jaesik Park ◽  
Sung Un Kim ◽  
Ho Joong Choi ◽  
Sang Hyun Hong ◽  
Min Suk Chae
Keyword(s):  
Liver Transplantation ◽  
Acute Kidney Injury ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Kidney Injury ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Final Study ◽  
History Of ◽  
D Dimer

This study aimed to determine the association between serum D-dimer levels and the risk of acute kidney injury (AKI) in patients undergoing living donor liver transplantation (LDLT). Clinical data of 675 patients undergoing LDLT were retrospectively analyzed. The exclusion criteria included a history of kidney dysfunction, emergency cases, and missing data. The final study population of 617 patients was divided into the normal and high D-dimer groups (cutoff: 0.5 mg/L). After LDLT, 145 patients (23.5%) developed AKI. A high D-dimer level (>0.5 mg/L) was an independent predictor of postoperative development of AKI in the multivariate analysis when combined with diabetes mellitus [DM], platelet count, and hourly urine output. AKI was significantly higher in the high D-dimer group than in the normal D-dimer group (odds ratio [OR], 2.792; 95% confidence interval [CI], 1.227–6.353). Patients with a high D-dimer exhibited a higher incidence of early allograft dysfunction, longer intensive care unit stay, and a higher mortality rate. These results could improve the risk stratification of postoperative AKI development by encouraging the determination of preoperative D-dimer levels in patients undergoing LDLT.

scholarly journals Long-term outcomes of living donor liver transplantation in patients with a prior history of nonhepatic malignancy

2020 ◽  
Vol 14 (1) ◽  
pp. 42-47
Author(s):  
Hidekazu Yamamoto ◽  
Yuzuru Sambommatsu ◽  
Sho Ibuki ◽  
Keita Shimata ◽  
Yasuhiko Sugawara ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Prior History ◽  
Long Term Outcomes ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
History Of

scholarly journals Outcomes of Living Donor Liver Transplantation in Patients With a History of Ruptured Hepatocellular Carcinoma

2021 ◽  
Vol 8 ◽  
Author(s):  
Hwi Yeol Lee ◽  
Suk Kyun Hong ◽  
Su young Hong ◽  
Sanggyun Suh ◽  
Eui Soo Han ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Surgical Resection ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Transarterial Embolization ◽  
Tumor Biology ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
History Of

Background: Liver transplantation (LT) is considered a contraindication in patients with a history of hepatocellular carcinoma (HCC) rupture because ruptured HCCs are classified as T4 in the current American Joint Committee on Cancer TNM system. This study aimed to assess living donor liver transplantation (LDLT) in these patients and elucidate the factors that may have affected their outcomes.Methods: Data of patients with a history of ruptured HCC who underwent LDLT between January 1999 and December 2019 were retrospectively reviewed.Results: Among 789 patients who underwent LDLT for HCC, five (0.64%) had a history of HCC rupture. Three patients (60%) were treated with transarterial chemoembolization (TACE) or transarterial embolization (TAE) for hemostasis, and two patients (40%) achieved spontaneous hemostasis. One of two patients who achieved spontaneous hemostasis underwent surgical resection and LT at 1 week and 6 years after the rupture, respectively. The other patient underwent LT 2 days after the rupture. Four patients (80%) survived for >5 years, while two patients (40%) experienced recurrence and succumbed during the median follow-up duration of 85.3 months (range, 12.4–182.7). The recurrence first developed at 4.3 and 17.0 months after LT; these patients were managed well using surgical resection for peritoneal seeding and TACE for intrahepatic HCC.Conclusion: LDLT can be considered a treatment method even in patients with a history of HCC rupture after full evaluation of tumor biology and risk of recurrence.

Adult-to-Adult Living-Donor Liver Transplantation

Swiss Surgery ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 227-236 ◽  
Author(s):  
Majno ◽  
Mentha ◽  
Berney ◽  
Bühler ◽  
Giostra ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Therapeutic Option ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Multidisciplinary Program ◽  
First Case ◽  
Living Donor Transplantation ◽  
The Right

Living donor liver transplantation is a relatively new procedure in which the right side of the liver is harvested in a healthy donor and transplanted into a recipient. After the first case in 1994, over 3000 cases have been done worldwide. This review summarizes the reasons why the procedure is needed, describes its main technical aspects, highlights the boundaries in which it can be done safely, summarizes the current experience worldwide and describes the main points of the program in our unit. We argue that living-donor transplantation is a viable alternative to a long time on the waiting list for several patients, and it can be performed safely and successfully provided that all precautions are undertaken to minimize the risks in the donor and to increase the chances of a good outcome in the recipients. If these prerequisites are met, and within the framework of a structured multidisciplinary program, we believe that living-donor liver transplantation should be funded by health insurances as a recognized therapeutic option.

Sign in / Sign up

Export Citation Format

Share Document